Drugs / BRX011
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07029945 Comparator | Jul 2025 → Nov 2026 expected | diffuse secondary choroid atrophy | Biojiva LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRX011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07029945 ↗ |
| Route | Oral | “Subjects will ingest BRX011 orally, as capsules.” NCT07029945 ↗ |